Results 151 to 160 of about 29,100 (241)

Wong-Type Dermatomyositis: An Extremely Rare Disease in Childhood

Dermatology Practical & Conceptual, 2019
Mario Diplomatico, Orsola Ametrano, Maria Elena Errico, Angela Mauro, Roberto Rega, Rita Sottile   +5 more
doaj   +1 more source

Editorial: Promoting patient-centered care for pediatric rheumatology across Africa. [PDF]

Front Pediatr
Hamdi W, Migowa A.
europepmc   +1 more source

Single‐Cell RNA Sequencing Informs Precision Targeting of Monogenic Lupus Associated With IKZF1 Haploinsufficiency

Arthritis &Rheumatology, Volume 78, Issue 6, Page 1231-1244, June 2026.
Objective This study aimed to investigate the mechanisms of immune dysregulation in a pediatric patient with monogenic lupus driven by IKZF1 haploinsufficiency. Methods Peripheral immune cells from a patient with IKZF1 haploinsufficiency, patients with lupus with no currently known genetic mutations, and healthy controls were analyzed using single‐cell
Qi Zheng, Yejun Tan, Zhaoling Wang, Yanjie Qian, Qian Ma, Danping Shen, Meiping Lu   +6 more
wiley   +1 more source

Telehealth triage in pediatric rheumatology: a diagnostically accurate tool to improve access to care. [PDF]

Diagnosis (Berl)
Aisenberg L, Rasooly IR, Weiss PF, Burnham J, Costello A.   +4 more
europepmc   +1 more source

Interleukin‐18 Levels Are Associated With Disease Course in Patients With Still Disease Treated With Interleukin‐1 Inhibitors

Arthritis &Rheumatology, Volume 78, Issue 6, Page 1327-1338, June 2026.
Objective To evaluate the prognostic utility of circulating interleukin‐18 (IL‐18) levels in predicting disease activity, macrophage activation syndrome (MAS), and disease course in patients with Still disease (SD) receiving first‐line IL‐1 inhibitors (IL‐1i).
Matteo Trevisan, Manuela Pardeo, Ivan Caiello, Claudia Bracaglia, Arianna De Matteis, Valentina Matteo, Elena Loricchio, Fabrizio De Benedetti, Giusi Prencipe   +8 more
wiley   +1 more source

Cyclophosphamide treatment with a comparison in both pediatric rheumatology and pediatric nephrology practices. [PDF]

Pediatr Rheumatol Online J
Gezgin Yildirim D, Orulluoglu EY, Yildiz C, Acari C, Dundar HA, Akaci O, Akinci N, Aliyev E, Alpman BN, Altug Gucenmez O, Arslanoglu Aydin E, Atmis B, Avar Aydin PO, Aydin F, Baba O, Baglan E, Bagrul I, Barut K, Basaran O, Bayrakci US, Belder N, Yucel BB, Buyukkaragoz B, Caglayan S, Cakan M, Celikel E, Demir F, Demir S, Demir Yigit Y, Demirkan FG, Dincel N, Dogantan S, Ekici Tekin Z, Genc E, Haslak F, Isguder R, Kara A, Kasap Cuceoglu M, Kaya Akca U, Kisaoglu H, Kisla Ekinci RM, Kızıldag Z, Kurt T, Kucukali B, Leventoglu E, Nalcacioglu H, Yener GO, Ozdel S, Ozdemir Atikel Y, Ozdemir Cicek S, Pektas Leblebiciler S, Serdaroglu E, Sonmez HE, Sunar Yayla EN, Surmeli Doven S, Sahin S, Sener S, Tanatar A, Tanidir M, Taskin SN, Tiryaki B, Tuncez S, Turkucar S, Uzun Kenan B, Yildiz N, Yilmaz K, Tabel Y, Dursun I, Canpolat N, Mir S, Peru H, Topaloglu R, Kaya Gurgoze M, Balat A, Bilginer Y, Celikel Acar B, Sozeri B, Unsal E, Kasapcopur O, Bakkaloglu SA.   +79 more
europepmc   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

Arthritis &Rheumatology, Volume 78, Issue 6, Page 1258-1267, June 2026.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, for the TULIP‐SC investigators   +12 more
wiley   +1 more source

The inequity of global healthcare in pediatric rheumatology. [PDF]

Best Pract Res Clin Rheumatol
Vilaiyuk S, Hadef D, Hamdi W, Scott C, Slamang W, Foster HE, Lewandowski LB.   +6 more
europepmc   +1 more source

OGFRL1 Deficiency Causes Chronic Recurrent Multifocal Osteomyelitis Via Pathologic Osteoclastogenesis, With Therapeutic Response to Tumor Necrosis Factor Inhibitor

Arthritis &Rheumatology, Volume 78, Issue 6, Page 1318-1326, June 2026.
Objective To verify the pathogenesis of the opioid growth factor receptor like‐1 (OGFRL1) loss‐of‐function variant (c.30del, p. F10Ffs*110) identified in a patient with chronic recurrent multifocal osteomyelitis (CRMO) and to investigate the underlying mechanism.
Wen Xiong, Yusha Wang, Tingyan He, Jinjian Fu, Ying Luo, Jinbo Wang, Jun Wang, Xiaomin Yu, Qing Zhou, Jun Yang   +9 more
wiley   +1 more source

Acute Disseminated Encephalomyelitis Presenting as Fever of Unknown Origin in a 4‐Year‐Old Boy: A Case Report

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT A 4‐year‐old boy presented with prolonged fever of unknown origin and systemic inflammation without early neurological signs. MRI revealed multifocal demyelination, and MOG antibodies were positive. He was diagnosed with ADEM and treated with steroids and IVIg, but relapsed twice, consistent with multiphasic disseminated encephalomyelitis ...
Pedro Pau
wiley   +1 more source